Full Year 2023 Investor Presentation
Novo NordiskⓇ
144
Investor presentation
Full year 2023
Resource allocation in Novo Nordisk is guided by investing in
future growth while delivering attractive shareholder returns
Corporate strategy guides resource allocation
Diabetes
Strengthen leadership by
offering innovative
medicines and driving
patient outcomes
Rare Disease
Secure a leading position
by leveraging full portfolio
and expanding into
adjacent areas
Novo
Nordisk
Way
Driving change
to defeat serious
chronic diseases
Sustainable business
Obesity
Strengthen leadership
through market
development and by offering
innovative medicines and
driving patient outcomes
Cardiovascular &
Emerging Therapy
Areas
Establish position in
cardiovascular disease and
build a presence in emerging
therapy areas
Expected primary sales growth drivers towards 2030
Waves of growth
GLP-1
Diabetes
ILLUSTRATIVE
Research technology
CETA
Rare disease
Obesity
care
platforms
Focus on driving sustained sales growth
•
Commercial investments in growth markets and products
•
R&D investments in future growth assets
R&D: Research and Development; CETA: Cardiovascular & Emerging Therapy Areas
2020
2025
2030View entire presentation